Bluesail Medical to acquire Swiss heart valve company NVT for RMB 1.39 billion

Bluesail Medical Co., Ltd. announced its intention to acquire 100% equity interest in New Valve Technology (NVT), a Swiss developer and manufacturer of transcatheter interventional heart valves, with a total consideration of RMB 1.39 billion for the acquisition and subsequent capital injection. The acquisition will expand Bluesail's portfolio in cardiovascular high-value consumables.

“On the evening of August 2, Bluesail Medical Co., Ltd. announced its intention to acquire 100% equity interest in New Valve Technology (NVT), a Swiss developer and manufacturer of transcatheter interventional heart valves, with a total consideration of RMB 1.39 billion for the acquisition and subseq”vcbeathealth.com

• 2 sources
• vcbeathealth.comLanfan Medical Acquires Swiss Heart Valve Company NVT to Enter High-Growth TAVR Market-VCBeatAug 4, 2019
• vcbeathealth.comBluesail Medical to Acquire 100% Equity of Swiss NVT for RMB 1.39 Billion to Enter Structural Heart Disease Therapy-VCBeatAug 5, 2019

Summarized from public sources; check the original articles before acting on it.